Status:
ACTIVE_NOT_RECRUITING
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Lead Sponsor:
Bayer
Conditions:
Thyroid Carcinoma
Eligibility:
All Genders
Brief Summary
This is a non-interventional, multi center post-authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma (DTC) and treated with Sorafenib within...
Eligibility Criteria
Inclusion
- Patients who start NEXAVAR treatment for radioactive iodine-refractory unresectable Differentiated Thyroid Carcinoma (DTC)
Exclusion
- Patients who have already received NEXAVAR treatment
Key Trial Info
Start Date :
June 27 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2025
Estimated Enrollment :
453 Patients enrolled
Trial Details
Trial ID
NCT02185560
Start Date
June 27 2014
End Date
November 30 2025
Last Update
July 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Japan